Alvogen settles U.S. Revlimid® patent litigation with Celgene
April 1, 2019

Alvogen settles U.S. Revlimid® patent litigation with Celgene 

  • Alvogen licensed to sell volume-limited amounts of generic lenalidomide in the U.S. beginning on a confidential date after the March 2022 date Celgene previously granted to Natco
  • Alvogen also licensed to sell generic lenalidomide in the U.S. without volume limitation beginning on January 31, 2026
  • The earliest licensed entry of any generic lenalidomide in the U.S. continues to be March 2022, based on settlements reached

Alvogen, Lotus Pharmaceutical (collectively, Alvogen) and Celgene Corporation (NASDAQ: CELG) today announced the settlement of their litigation relating to patents for REVLIMID® (lenalidomide).

As part of the settlement, the parties will file Consent Judgments with the United States District Court for the District of New Jersey that enjoin Alvogen from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as described below.

In settlement of all outstanding claims in the litigation, Celgene has agreed to provide Alvogen with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the United States beginning on a confidential date that is some time after the March 2022 volume-limited license date that Celgene previously provided to Natco. For each consecutive twelve-month period (or part thereof) following the volume-limited entry date until January 31, 2026, the volume of generic lenalidomide sold by Alvogen cannot exceed certain agreed-upon percentages. Although the agreed-upon percentages are confidential, they increase gradually each period to no more than a single-digit percentage in the final volume-limited period. In addition, Celgene has agreed to provide Alvogen with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States beginning no earlier than January 31, 2026.

Alvogen’s ability to market lenalidomide in the U.S. will be contingent on its obtaining approval of an Abbreviated New Drug Application.

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.